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Objective: To assess the prevalence of underweight (UW), overweight (OW), and obesity in
children and adolescents with type 1 diabetes (T1D).
Methods: An international cross-sectional study including 23 026 T1D children (2-18 years,
duration of diabetes ≥1 year) participating in the SWEET prospective, multicenter diabetes
registry. Body mass index SD score (BMI-SDS) was calculated using the World Health Organi-
zation BMI charts. Children were categorized as UW (BMI-SDS < −2SD), OW (+1SD < BMI-
SDS ≤ +2SD), and obese (OB) (BMI-SDS > +2SD). Hierarchic regression models were applied
with adjustment for sex, age, and duration of diabetes.
Results: The prevalence of UW, OW, and obesity was: 1.4%, 22.3%, and 7.3% in males and
0.6%, 27.2%, and 6.8% in females. Adjusted BMI-SDS was significantly higher in females than
in males (mean  SEM: 0.54  0.05 vs 0.40  0.05, P < 0.0001). In males, BMI-SDS signifi-
cantly decreased by age (P < 0.0001) in the first three age categories 0.61  0.06 (2 to
<10 years), 0.47  0.06 (10 to <13 years), 0.34  0.05 (13 to <16 years). In females, BMI-
SDS showed a U-shaped distribution by age (P < 0.0001): 0.54  0.04 (2 to <10 years),
0.39  0.04 (10 to <13 years), 0.55  0.04 (13 to <16 years). BMI-SDS increased by diabetes
duration (<2 years: 0.38  0.05, 2 to <5 years: 0.44  0.05, and ≥5 years: 0.50  0.05,
P < 0.0001). Treatment modality did not affect BMI-SDS. Adjusted HbA1c was significantly
higher in females than in males (8.20%  0.10% vs 8.06%  0.10%, P < 0.0001). In both gen-
ders, the association between HbA1c and BMI-SDS was U-shaped with the highest HbA1c in
the UW and obesity groups.
Conclusions: The high rate of OW and obesity (31.8%) emphasize the need for developing
further strategies to prevent and treat excess fat accumulation in T1D.
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1 | INTRODUCTION
In the last decades, a rapid increase in the prevalence of obesity in
children and adolescents has occurred worldwide.1,2 Similarly, an
increase in the prevalence of type 1 diabetes (T1D) was also
observed.3,4 The obesogenic environment is likely to play a role in this
process.5 However, the introduction of more intensive and flexible
insulin regimens (ie, multiple daily insulin injections and insulin pumps)
may be a contributing factor in people with diabetes by increasing fat
accumulation in spite of improved metabolic control.6,7
Insulin resistance and cardiovascular risk factors are associated
with increased fat mass.8,9 Obese (OB) people with T1D have lower
insulin sensitivity and a higher cardiovascular risk profile than the
non-OB people with T1D.10–13 Underweight (UW) affects a minority
of the pediatric population.14 However, data in adults suggest that
UW individuals with established T1D are more prone to diabetic
ketoacidosis and severe hypoglycemia than those with normal weight
(NW).15 Therefore, the increase in the amplitude of the deviation in
excess or decrease from the median body mass index (BMI) for age
and gender is associated with increased health risk for children and
adolescents with T1D. Consequently, it is crucial to identify subjects
with at risk BMI and to ensure specific care for managing children
with BMI in the UW and overweight (OW)/obesity categories as well
as to prevent these conditions.
To the best of our knowledge, there is a scarcity of available data
on the prevalence and the geographical distribution of UW, OW, and
obesity in large cohorts of children and adolescents with T1D.16–18
A previous study based on the DPV (Diabetes-Patienten-Ver-
laufsdokumentation) data reported that BMI of children and adoles-
cents with T1D is higher compared with healthy children measured in
the same year.19 Especially, very young children and adolescent girls
were at risk for OW independent of annual trends. Apart from a study
comparing UW, OW, and obesity in children with T1D conducted in
Germany, Austria, and United States,14 there is a lack of international
data using the BMI-SD score (BMI-SDS) of the World Health Organi-
zation (WHO).20,21
Therefore, the aims of this study were to assess the prevalence of
UW, OW, and obesity of children and adolescents with T1D in a large
international cohort of children and adolescents and to investigate the
association between the BMI-SDS and gender, age, duration of diabe-
tes, treatment regimen, and metabolic control.
2 | METHODS
The analysis was based on data from the SWEET “Better control in
Pediatric and Adolescent diabeteS: Working to crEate CEnTers of
Reference,” a prospective, multicenter, standardized diabetes patient
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registry. SWEET is an international consortium of pediatric diabetes
centers created with the aim of improving the care of children with
T1D through sharing the best practices and the collection of clinical
outcome data in large cohorts of patients.22 Currently, the SWEET
network includes 55 pediatric diabetes centers from all continents.
For the data collection, centers used the DPV software (https://
sweet.zibmt.uni-ulm.de/software.php), DIAMAX Digital Exchanges,
data download of existing registries or local databases. Anonymized
demographic and clinical data were transferred twice yearly to the
SWEET database at the Institute of Epidemiology and Medical Biome-
try, University of Ulm, Ulm, Germany.23 Inconsistent and implausible
data were reported back for verification or correction after each data
upload.
As of March 2017, 374 728 visits by 34 542 patients with diabe-
tes were available in the SWEET database. For the present analysis,
patients aged 2 to 18 years with T1D and duration of diabetes
≥1 year were included. Patients without documentation of gender,
age, duration of diabetes, and BMI-SDS were excluded (Figure 1).
Datasets were aggregated over the most recent year of treatment for
each patient. In the final study cohort, 23 026 youths with T1D were
included. The current analysis involved 25 European countries (42 cen-
ters) and 12 countries (13 centers) outside Europe.
Height was measured in 0.5 cm and weight was determined in
kilogram. The BMI was calculated as weight (kilograms) divided by
height (meters) squared. BMI-SDS was calculated using the WHO
BMI charts.22 Children were categorized as UW (BMI-SDS < −2SD),
NW (2SD ≤ BMI-SDS ≤ +1SD), OW (+1SD < BMI-SDS ≤ +2SD), and
OB (BMI-SDS > +2SD).24
Metabolic control was assessed by glycated hemoglobin (HbA1c),
which was measured locally in each center. To adjust for differences
between laboratories, multiple of the mean (MOM) method was used
to mathematically standardize HbA1c values to the reference range of
the Diabetes Control and Complications Trial (DCCT, 21-43 mmol
mol−1 [4%-6%]).25 Treatment modality was defined as conventional
therapy (CT, ≤3 injection time points per day), intensified conventional
therapy (ICT, 4-8 injection time points per day), and insulin pump (con-
tinuous subcutaneous insulin infusion [CSII]). Insulin dose was defined
as the total daily units of insulin divided by the body weight in
kilograms. Age was classified into 2 to <10, 10 to <13, 13 to <16,
16 to ≤18 years. Duration of diabetes was grouped into <2, 2 to <5,
and ≥5 years.
2.1 | Statistical analysis
Results are presented as median with quartiles or numbers and per-
centages. Wilcoxon, Kruskal-Wallis and χ2-tests were performed to
compare demographic characteristics and clinical outcomes. To adjust
for multiple testing, P-values were corrected by false discovery
rate (FDR).
Hierarchic regression models were adjusted for age, gender, and
duration of diabetes. In order to account for variation among pediatric
diabetes centers, center was entered as a random effect in the
models. Adjusted mean with 95% confidence intervals were used to
describe the differences. To adjust for multiple comparisons, Tukey-
Kramer test was used.
A two-sided P-value <0.05 was considered statistically significant.
Statistical analysis was performed using Statistical Analysis Software
9.4 (SAS, SAS Institute Inc., Cary, North Carolina).
3 | RESULTS
Clinical characteristics of study participants are shown in Table 1. In
both genders, diabetes duration, BMI, HbA1c, and insulin dose per kg
body weight significantly (all P < 0.0001) increased with age. More-
over, the proportion of subjects treated with the ICT significantly
increased by age category whereas the proportion of those treated
with pumps significantly decreased (P < 0.0001).
The prevalence of UW, NW, OW, and obesity was: 1.4%, 69.0%,
22.3%, and 7.3% in males and 0.6%, 65.4%, 27.2%, and 6.8% in
females. Overall, the prevalence of UW was significantly higher in
males than in females (P < 0.0001), whereas that of OW was signifi-
cantly higher in females (P < 0.0001). In the youngest age group, the
prevalence of obesity was significantly higher in males than females
(M: 9.6% vs F: 6.2%; P < 0.0001) whereas the opposite was found in
the eldest (M: 6.2% vs F: 7.8%; P < 0.0001). In children older than
10 years, the prevalence of OW was significantly higher in females (F:
28.2% vs M: 21.5%; P < 0.05) whereas the prevalence of UW was sig-
nificantly higher in males (M: 1.65% vs F: 0.67%; P < 0.0001)
(Figure 2).
3.1 | Adjusted results
Adjusted for age and gender BMI-SDS significantly increased with dia-
betes duration (<2 years: 0.38  0.05; 2-5 years: 0.44  0.05; and
>5 years: 0.50  0.04; P < 0.0001). However, BMI-SDS significantly
(P < 0.0001) increased by diabetes duration just in females (<2 years:
0.39  0.05; 2-5 years: 0.49  0.04; and >5 years: 0.60  0.04) but
not in males (<2 years: 0.39  0.06; 2-5 years: 0.41  0.05; and
>5 years: 0.41  0.05; P = not significant, NS).
Adjusted for age and duration of diabetes, females had signifi-
cantly higher BMI-SDS than males (0.54  0.05 vs 0.40  0.05,
P < 0.0001). Similar to unadjusted data, BMI-SDS in malesFIGURE 1 Selection of study population
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significantly decreased from the first to the third age category
(P < 0.0001), whereas BMI-SDS in females showed a significant
reduction from the first to the second and the third age category
(P < 0.0001), followed by a significant increase in the fourth age cate-
gory (P < 0.05) (Figure 3).
HbA1c was significantly higher in females (8.20%  0.10% vs
8.06%  0.10%, P < 0.0001). In both genders, HbA1c was signifi-
cantly (P < 0.05) higher in UW and OB subjects than in NW persons
(Figure 4). In males, HbA1c was significantly (P < 0.05) higher in UW
and OB than in OW subjects. In females, HbA1c was significantly
(P < 0.001) higher in OW than in normal subjects. No other significant
differences were found among BMI categories.
BMI-SDS was not different in children treated with CT
(0.42  0.05), ICT (0.48  0.05), or CSII (0.48  0.05) (all P > 0.53).
Daily insulin dose per body weight for UW subjects was significantly
higher than in the other BMI categories (P < 0.01). Daily insulin dose
per body weight was not significantly different between NW, OW,
and OB youth and between MDI and insulin pump users. Similar
results were found analyzing Norther vs Southern Europe only (data
not shown).
4 | DISCUSSION
The mean prevalence of OW and obesity was approximately 30% in
the sample of youth participating in this study. This result is in
accordance with the reported prevalence in the general population,
especially in industrialized countries.26 Therefore, it is likely that the
impact of factors such as genetic predisposition and the pressures
from an obesogenic environment in promoting excess body fat accu-
mulation in children and adolescents also impact youth with T1D. This
is in spite of exposure to a nutritional education program and to regu-
lar clinical follow-up, which should theoretically contribute to mainte-
nance of body weight.27
However, the main finding of this large worldwide study of chil-
dren with T1D was that diabetes duration, adjusted for age, was sig-
nificantly associated with higher BMI-SDS.28,29 Type 1 diabetes and
its treatment therefore appear to promote excess weight gain. Several
factors, which are common in adolescents with or without T1D, such
as sedentary behavior, reduced exercise (especially in females), and
unhealthy eating habits, may contribute to favor a positive energy bal-
ance.30,31 Other factors favoring body fat accumulation are specific to
diabetes, including extra calorie intake to prevent or correct hypogly-
cemia, the consumption of low carbohydrate high fat foods, to reduce
postprandial glucose increase, and the chronic exposure of the periph-
eral tissues to non-physiologic hyperinsulinemia due to the subcuta-
neous insulin injections or infusion via insulin pump.32–42 Nutritional
strategies to reduce nocturnal hypoglycemia, if insulin pump or long-
acting analog insulin (such as glargine or degludec insulin) are not
used, include the ingestion of a bedtime snack containing carbohy-
drates and protein, although the American Diabetes Association
FIGURE 2 Prevalence (%) of underweight (UW), normal weight (NW), overweight (OW), and obesity (OB) by gender and age categories. Children
were categorized as UW (BMI-SDS < −2SD), NW (−2SD ≤ BMI-SDS ≤ +1SD), OW (+1SD < BMI-SDS ≤ +2SD), and OB (BMI-SDS > +2SD) in
according with World Health Organization (WHO) standards. *P < 0.0001; †P < 0.03
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(ADA) and the Endocrine Society reported the absence of consensus
on this practice.32 Moreover, nocturnal hypoglycemia in people with-
out diabetes stimulates spontaneous food intake the following morn-
ing, with special preference for carbohydrates.33 Similar mechanisms
may contribute to the frequently observed body weight gain in
insulin-treated patients. Due to the strong relationship between
carbohydrate intake and postprandial glucose profile, modification of
diet composition, with a reduction of carbohydrate, could be a poten-
tial strategy for limiting postprandial glucose excursions and fluctua-
tions at least in the short term, although appropriate carbohydrate
and fat intake was associated with lower HbA1c.34,37–39 Moreover, a
low carbohydrate intake is associated with less favorable dietary
FIGURE 3 Body mass index-SD score (BMI-SDS) compared by age groups and gender adjusted for duration of diabetes. Hierarchic regression
model with center as random variable was applied. Data are shown as least-squared means and 95% confidence intervals. Females (red dots): 2 to
<10 years vs 10 to <13 years, *P < 0.001; 10 to <13 years vs 13 to <16 years, *P < 0.0001; 13 to <16 years vs 16 to 18 years, P = not
significant, NS. Males (blue dots): 2 to <10 years vs 10 to <13 years, *P < 0.001; 10 to <13 years vs 13 to <16 years, *P < 0.0001; 13 to
<16 years vs 16 to 18 years, P = not significant, NS
FIGURE 4 HbA1c (%) compared by body mass index-SD score (BMI-SDS) (categorical) and gender adjusted for age (categorical) and diabetes
duration (categorical). Hierarchic regression model with center as random variable was applied. Data are showed as least-squared means and 95%
confidence interval. Females (red dots): underweight (UW) vs normal weight (NW) P < 0.05; NW vs overweight (OW) P < 0.0001; OW vs obese
(OB) P = not significant, NS. Males (blue dots): UW vs NW P < 0.01; NW vs OW P = not significant, NS; OW vs OB P < 0.05
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nutrient composition, leading to overconsumption of protein and
fat.35,36,40 Additionally, subcutaneous insulin injection and infusion
exposes the body to higher peripheral insulinemia than that physiolog-
ically secreted by the pancreas in non-diabetic subjects41; this chronic
hyperinsulinemia promotes fat deposition.42
Data from the DCCT showed that those subjects exposed to
intensive insulin therapy compared to those on CT had a reduced inci-
dence and progression of microvascular complications, reduced risk
factors for macrovascular complications, and lower incidence of major
cardiovascular disease events.6,43,44 While these outcomes are favor-
able, intensive treatment was also associated with a higher incidence
of excess weight gain, central obesity, insulin resistance, dyslipidemia,
and elevated blood pressure. Accordingly, follow-up of DCCT subjects
in the Epidemiology of Diabetes Interventions and Complications
(EDIC) Study reported important changes in lipid levels and blood
pressure in subjects with excessive weight gain with intensive therapy
that were similar to those seen in the insulin resistance syndrome.45
BMI in children with T1D using intensive insulin regimens is reported
increased compared with children treated with less intense therapy
(≤3 insulin injections per day).46,47 On the contrary, the results of our
study showed that, adjusting for confounders, BMI-SDS was not
affected by the treatment regime. This is in accordance with the data
reported by a study with German and Austrian children and adoles-
cents.48 The most likely explanation of our findings is that lower insu-
lin dose per kg body weight in subjects using insulin pump compared
to MDI contributes to reduced insulin exposure and therefore less fat
deposition in the peripheral tissues.41,42,49 Interestingly, in our popula-
tion the use of pumps decreased with age, in agreement with previous
studies.50,51 Several factors contribute to this finding, such as the
decreasing influence of parents in diabetes management during
puberty, the impact of the peer group and the comparison within
other adolescents, etc.52 Some of these factors also affect lifestyle,
diet, and physical activity, potentially contributing to adiposity accu-
mulation in adolescence.21
In both genders, BMI-SDS decreased from prepuberty to puberty,
then further decreased in the postpubertal age category for males but
increased in females. The difference between genders is likely the
result of greater fat gain during and after puberty for girls.53 Three
main factors may contribute to this finding: higher insulin resistance in
females than males, alterations in GH/IGF-1 axis in patients with T1D,
and the influence of sex steroids.6 Selective insulin resistance during
puberty leads to compensatory hyperinsulinemia, amplifying insulin's
effect on amino acid metabolism and thereby facilitating protein anab-
olism.54 This physiologic process is increased in adolescents with T1D
due to lower insulin sensitivity than non-diabetic peers.55 Abnormali-
ties of the growth hormone/IGF-1 axis have been reported in adoles-
cents with T1D, with increased GH secretion and incomplete
suppression of GH by IGF-1, leading to a higher risk of hypoglycemia
and weight gain.56 Girls seem to be more sensitive to GH/IGF-1 per-
turbations than boys, due to their much lower increase of
testosterone.57
This study also found an association between BMI-SDS and the
metabolic control. UW and OB children and adolescents had signifi-
cantly higher HbA1c than NW patients. The cross-sectional design of
the study did not allow assessment of the cause-effect relationship
between variables. Nevertheless, in accordance with the available evi-
dence, inadequate diabetes control leading to chronic hyperglycaemia
is likely associated with energy loss via glucosuria and subsequent
weight reduction, spontaneous reduction of food intake promoted by
ketoacidosis condition, and increased energy expenditure due to
increased protein turnover and gluconeogenesis.58 The high HbA1c
found in subjects with a high BMI-SDS may be due to chronic positive
energy balance promoted by inappropriate dietary behavior and eat-
ing disorders accompanied by inadequate insulin treatment, which are
more common in adolescents than in younger children.36,59,60
The strengths of this study were: the large sample size, a world-
wide dataset, and the SWEET data quality control. Weaknesses
include the fact that the SWEET registry is not population-based and
the researchers did not have access to subjects' ethnic backgrounds,
nutritional habits, data on adjunctive therapies, different insulin regi-
mens used, or physical activity history. Therefore, prevalence rates
are not applicable to the entire population of children and adolescents
with T1D. Additionally, BMI-SDS, though widely accepted in large epi-
demiological studies as a reasonably accurate measure of body size
and an index of fatness, is not actually a measure of fatness. Availabil-
ity of a direct measure of body fat mass might provide a better expla-
nation of the relationship between adiposity and contributing
variables. Assessment of body fat distribution could also be useful, as
it may be a stronger factor than total fat mass in promoting cardiovas-
cular risk.61 Although this study assessed BMI by the WHO charts,
comparisons between study subjects and appropriate age and gender
populations or other cohorts of diabetic children and adolescents
would be useful for future analysis.
In conclusion, 1 of 3 children and adolescents with T1D was OW
or OB whereas 1 of 100 was UW. On average, females had higher
BMI-SDS than males and BMI-SDS increased with diabetes duration.
UW and OB children and adolescents had the higher HbA1c. These
results emphasize the need for developing further strategies to pre-
vent and treat excess fat accumulation in T1D as it is strongly recom-
mended for the general population.
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